Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2015MedicineOpen Access

Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does baseline platelet count predict major bleeding in patients receiving vitamin K antagonists for acute venous thromboembolism?

Population

37,000 patients with acute venous thromboembolism receiving long-term therapy with vitamin K antagonists…

Comparison

Long-term therapy with vitamin K antagonists in… vs Patients with normal baseline platelet count…

Design

Cohort

Follow-up

mean 192 days

Authors

MGMatteo Giorgi‐PierfranceschiPMPierpaolo Di MiccoCCChiara Cattabiani

Discussion

Loading...

Member takes

Overview

Extreme platelet counts were associated with higher VKA bleeding risk in VTE; hypothesis-generating and should not yet change practice.

Structured PICO

Does baseline platelet count predict major bleeding in patients receiving vitamin K antagonists for acute venous thromboembolism?

P
Population
37,000 patients with acute venous thromboembolism (VTE) receiving long-term therapy with vitamin K antagonists (VKAs) from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry database.
I
Intervention
Long-term therapy with vitamin K antagonists (VKAs) in patients with abnormal baseline platelet counts (very low <100,000/μL, low 100,000-150,000/μL, high 300,000-450,000/μL, or very high >450,000/μL).
C
Comparator
Patients with normal baseline platelet count (150,000-300,000/μL) receiving long-term therapy with vitamin K antagonists (VKAs).
O
Outcome
Rate of major bleeding during the course of VKA therapy.safety

There is a nonlinear U-shaped relationship between baseline platelet count and major bleeding risk in VTE patients treated with VKAs, with both very low and very high counts associated with increased bleeding.

Cite This Study

Giorgi‐Pierfranceschi et al. (2015) studied this question.

synapsesocial.com/papers/6a8ba5d1e76aab33123383bfhttps://doi.org/10.1097/md.0000000000001915
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Canadian Consensus Recommendations on the Management of Venous Thromboembolism in Patients with Cancer. Part 1: Prophylaxis2015 · 71 citations
  2. 2Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis2002 · 1,872 citations
  3. 3Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management2015 · 269 citations
  4. 4Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 20142015 · 1,374 citations
  5. 5Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort2012 · 221 citations